Plain-English translation of NCT05765110 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers want to understand whether analyzing how people speak—in detail using computers—can reliably detect changes in movement, mood, and thinking that happen in Parkinson's disease. Speech is complex and naturally reflects all three of these areas of health at the same time. This study will record and analyze speech from people with Parkinson's disease (some who have had deep brain stimulation surgery and some who haven't) and from healthy volunteers, to see if speech patterns can become a useful tool for doctors to monitor how well treatments are working.
Parkinson's disease affects how people move, think, and feel, and these abilities naturally go up and down throughout the day. Current ways of checking how someone is doing require office visits and subjective judgments from doctors. If speech analysis could reliably track these changes, it might help doctors adjust treatment more quickly and accurately, and even allow patients to monitor themselves at home.
You likely qualify if…
You likely don't qualify if…
You will be asked to speak naturally while researchers record and analyze your speech using computer software. You may be shown pictures designed to bring up certain emotions to see how that changes your speech patterns. The study will look at how your speech reflects your movement ability, thinking, and mood—both in the moment and over time. Visits will likely take place at the University Hospital Bern, and the exact duration and number of visits will be explained during the consent process.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Czechia
Switzerland
Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
Czech Technical University in Prague
Enrollment target
~80 participants
Started
January 2023
Primary completion
December 2026
Age range
30 Years – 75 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Paul Krack, Prof.
Insel Gruppe AG, University Hospital Bern
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.